Antibiotic product, use and formulation thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/20
A61K-009/48
A61K-009/50
A61K-009/16
출원번호
US-0275525
(2011-10-18)
등록번호
US-9144548
(2015-09-29)
발명자
/ 주소
Burnside, Beth A.
Flanner, Henry H.
Rowlings, Colin
출원인 / 주소
Shionogi Inc.
대리인 / 주소
MH2 Technology Law Group, LLP
인용정보
피인용 횟수 :
0인용 특허 :
270
초록▼
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
대표청구항▼
1. A once-a-day antibiotic product comprising: first, second, and third antibiotic dosage forms, each of said antibiotic dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier,said first antibiotic dosage form being a delayed release dosage form,said second and thi
1. A once-a-day antibiotic product comprising: first, second, and third antibiotic dosage forms, each of said antibiotic dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier,said first antibiotic dosage form being a delayed release dosage form,said second and third antibiotic dosage forms being delayed sustained release dosage forms comprising:a sustained release component and a delayed release component,wherein the sustained release component comprises nitrocellulose, an acrylic acid derivative or a polyethylene glycol with a molecular weight above 8,000 daltons,wherein the delayed release component comprises a polyethylene glycol with molecular weight above 4,000 daltons, a wax, a paraffin, cellulose acetate, cellulose acetate pthalate, or anionic polymers of methacrylic acid and methacrylates with a COOH groupwherein said second dosage form initiates release of antibiotic at about the same time as said first dosage form initiates release of antibiotic and Cmax of the total antibiotic released from said antibiotic product is achieved in less than about 12 hours from initial release of antibiotic and said once-a-day antibiotic product contains the total dosage of the at least one antibiotic for a twenty-four hour period. 2. The product of claim 1, wherein the Cmax for the product is reached no earlier than four hours after initial release of antibiotic. 3. The product of claim 1, wherein the antibiotic released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after initial release of antibiotic. 4. The product of claim 1, wherein the product is an oral dosage form. 5. The product of claim 1, wherein the antibiotic released from the second dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the first dosage form. 6. The product of claim 1, wherein the antibiotic released from the third dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the second dosage form. 7. The product of claim 1, wherein the first dosage form contains about 20-70% of the total dosage of antibiotic, the second dosage form contains about 10-70% of the total dosage of antibiotic, and the third dosage form contains about 10-70% of the total dosage of antibiotic. 8. The product of claim 1, wherein the first dosage form contains about 25-66% of the total dosage of antibiotic, the second dosage form contains about 15-60% of the total dosage of antibiotic, and the third dosage form contains about 15-60% of the total dosage of antibiotic. 9. The product of claim 1, wherein the first dosage form contains about 33-60% of the total dosage of antibiotic, the second dosage form contains about 25-50% of the total dosage of antibiotic, and the third dosage form contains about 25-50% of the total dosage of antibiotic. 10. The product of claim 1, further comprising a fourth antibiotic dosage form, said fourth antibiotic dosage form being either a sustained or a delayed release dosage form and comprising at least one antibiotic and a pharmaceutically acceptable carrier and wherein said at least one antibiotic released from said fourth antibiotic dosage form reaches a Cmax after Cmax is achieved for antibiotic released from each of said first, second, and third dosage forms. 11. The product of claim 10, wherein the Cmax for the product is reached no earlier than four hours after initial release of antibiotic. 12. The product of 10, wherein the antibiotic released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after initial release of antibiotic. 13. The product of 10, wherein the antibiotic released from the second dosage form reaches a Cmax in no more than about 4 hours after initial release of antibiotic. 14. The product of 10, wherein the product is an oral dosage form. 15. The product of 10, wherein the antibiotic released from the second dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the first dosage form. 16. The product of 10, wherein the antibiotic released from the third dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the second dosage form. 17. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 1, once-a-day. 18. The product of claim 1, wherein the acrylic acid derivative is a copolymer of acrylate and methacrylates with quarternary ammonium groups. 19. The product of claim 1, wherein the antibiotic is amoxicillin.
Hancock, Robert E. W.; Gough, Monisha A.; Patrzykat, Aleksander; Woods, Donald; Jia, Xiaoyan, Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.
Moenning Stephen P., Apparatus and method for protecting a port site opening in the wall of a body cavity utilizing a sealing member and a biologically active compound.
Chungi, Shubha; Iorio, Theodore L., Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin.
Elger Gordon A. (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Landbeach GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Cambridge GBX), Controlled release pharmaceutical composition.
Yang S. Shirley (Succasunna NJ) Boisvert Wayne (Randolph NJ) Muhammad Nouman A. (Long Valley NJ) Weiss Jay (East Brunswick NJ), Controlled release tacrine drug delivery systems and methods for preparing same.
Rhodes John (25 Nantfawr Road Cyncoed ; Cardiff ; South Glamorgan CF2 6JO GBX) Evans Brian K. (9 Merevale ; The Common Dinas Powis ; South Glamorgain CF6 4HS GBX), Delayed release oral dosage forms for treatment of intestinal disorders.
Rivett Ernest Lionel Gilbert,GBX ; Grimmett Francis Walter,GBX ; Hartnell Michael William,GBX, Delayed release pharmaceutical formulation containing a .beta.-lactam antibiotic.
Jordan Maureen L. (Mt. View CA) Ayer Atul D. (Palo Alto CA) Magruder Paul R. (Palo Alto CA) Edgren David E. (El Granada CA), Dosage form for delivering acetaminophen or phenylpropanolamine.
Monkhouse Donald ; Yoo Jaedeok ; Sherwood Jill K. ; Cima Michael J. ; Bornancini Esteban, Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof.
Greco Ralph S. (Princeton NJ) Harvey Richard A. (East Brunswick NJ) Trooskin Stanley Z. (North Brunswick NJ), Drug bonded prosthesis and process for producing same.
Henley, Julian L.; Chang, Kuo Wei; Potter, Joseph; Goldberg, Dennis I.; Porter, Christopher H.; Porcelli, V. Lorenzo, Electrokinetic delivery of medicaments.
Gudipati, Manga R; Jushchyshyn, John M; Palepu, Nageswara R; Venkatesh, Gopadi M, Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Czernielewski Janusz,FRX ; Allec Josiane,FRX ; Bouclier Martine,FRX, Medicaments based on metronidazole or on a synergic mixture of metronidazole and clindamycin.
Arvesen James N. (Princeton NJ), Method and apparatus for determining the minimum concentration of antibiotic necessary to at least inhibit microorganism.
Smith James W. (Indianapolis IN) Bartlett Marilyn S. (Indianapolis IN) Queener Sherry F. (Indianapolis IN), Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine.
Shimamura Tadakatsu (4-4 ; Nishihara 1-chome ; Shibuya-ku Tokyo JPX), Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus .
Cagle, Gerald; Abshire, Robert L.; Stroman, David W.; McLean, Celeste H.; Clark, Linda L.; Yanni, John M., Methods for treating otic and ophthalmic infections.
Moro, Daniel G.; Callahan, Howard; Nowotnik, David, Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds.
Wong Patrick S. L. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Eckenhoff James B. (Los Altos CA) Larsen Steven D. (Dublin CA) Huynh Hoa T. (Fremont CA), Multi-unit delivery system.
Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Multiple-delayed released antibiotic product, use and formulation thereof.
Raad Isaam (Houston TX) Sherertz Robert (Winston-Salem NC), Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and.
Burnside Beth A. ; Guo Xiaodi ; Fiske Kimberly ; Couch Richard A. ; Treacy Donald J. ; Chang Rong-Kun ; McGuinness Charlotte ; Rudnic Edward M., Oral pulsed dose drug delivery system.
Burnside, Beth A.; Guo, Xiaodi; Fiske, Kimberly; Couch, Richard A.; Treacy, Donald J.; Chang, Rong-Kun; McGuinness, Charlotte M.; Rudnic, Edward M., Oral pulsed dose drug delivery system.
Infeld Martin H. (Upper Montclair NJ) Malick A. Waseem (Edison NJ) Shah Navnit H. (Clifton NJ) Phuapradit Wantanee (Kearny NJ), Pharmaceutical compositions with constant erosion volume for zero order controlled release.
Amano Takehiro (Urawa JPX) Goi Masami (Saitama JPX) Sekiuchi Kazuto (Tatebayashi JPX) Yoshida Tomomichi (Omiya JPX) Hasegawa Masahiro (Omiya JPX), Process for preparing erythromycin A oxime or a salt thereof.
Patt Tom E. (Kalamazoo MI) Argoudelis Alexander D. (Portage MI) Marshall Vincent P. (Kalamazoo MI), Process for preparing lincomycin and clindamycin ribonucleotides.
D'Silva, Joe, Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface.
Ku Yi-Yin ; Riley David A. ; Lee Elaine C. ; Tien Jien-Heh, Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives.
Avrutov, Ilya; Lifshitz, Igor; Borochovitz, Ronen; Masarwa, Basem; Schwartz, Edi, Processes for preparing clarithromycin polymorphs and novel polymorph IV.
Panoz Donald (Tuckerstown BMX) Corneille Gilbert (Paris FRX), Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained the.
Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Elmhurst NY) Gaylord Norman G. (New Providence NJ), Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose.
Sheth Nitin V. (Middletown NY) Valorose ; Jr. Joseph J. (Montgomery NY) Ellway Keith A. (Washingtonville NY) Ganesan Madurai G. (Suffern NY) Mooney Kieran G. (Warwick NY) Johnson Jerry B. (Upper Rive, Pulsatile once-a-day delivery systems for minocycline.
Baron ; Jr. Joseph J. (Morris Plains NJ) Nowakowski Tamara (Boonton Township ; Morris County NJ) Farrington Thomas A. (Sparta NJ) Mahn Frederick R. (Verona NJ), Retention and/or drainage and/or dewatering aid.
Philippe Michel (Antony FRX) Sebag Henri (Paris FRX) Dupuis Didier (Le Raincy FRX) Rougier Andr (Dammartin en Goele FRX), Retinoic esters of antibiotics and pharmaceutical and cosmetic compositions containing them.
Johnson Donald A. (Miami Lakes FL) Wearley Lorraine (Westfield NJ) Galeos Rebecca (Bloomfield NJ) Sequeira Joel A. (New York NY), Stable hydrated cephalosporin dry powder for oral suspension formulation.
Christensen Burton G. ; Cho In-Seop ; Glinka Tomasz W. ; Hecker Scott J., Substituted-pyridinyl cephalosporin antibiotics active against methicillin resistant bacteria.
Patel Satischandra P. (Livingston NJ) Bhalani Vinayak T. (Morris Plains NJ), Sustained release composition for oral administration of active ingredient.
Cima Michael (Lexington MA) Sachs Emanuel (Somerville MA) Fan Tailin (Cambridge MA) Bredt James F. (Watertown MA) Michaels Steven P. (Melrose MA) Khanuja Satbir (Cambridge MA) Lauder Alan (Boston MA), Three-dimensional printing techniques.
Sachs Emanuel M. (Somerville MA) Haggerty John S. (Lincoln MA) Cima Michael J. (Lexington MA) Williams Paul A. (Concord MA), Three-dimensional printing techniques.
Sachs Emanuel M. (Somerville) Haggerty John S. (Lincoln) Cima Michael J. (Lexington) Williams Paul A. (Concord MA), Three-dimensional printing techniques.
Stiefel Werner K. (Coral Gables FL) Popp Karl F. (Schodack Landing NY), Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof.
Bax Richard Peregrine,GBX, Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.